WCM Investment Management LLC Acquires 595 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

WCM Investment Management LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 3.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,540 shares of the biotechnology company’s stock after purchasing an additional 595 shares during the quarter. WCM Investment Management LLC’s holdings in BioMarin Pharmaceutical were worth $1,148,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BMRN. GAMMA Investing LLC boosted its holdings in shares of BioMarin Pharmaceutical by 56.1% during the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company’s stock worth $55,000 after buying an additional 281 shares during the period. CWM LLC lifted its position in BioMarin Pharmaceutical by 363.1% during the third quarter. CWM LLC now owns 11,106 shares of the biotechnology company’s stock worth $781,000 after acquiring an additional 8,708 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of BioMarin Pharmaceutical by 437.5% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,720 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 1,400 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of BioMarin Pharmaceutical by 87.2% during the third quarter. Exchange Traded Concepts LLC now owns 16,663 shares of the biotechnology company’s stock worth $1,171,000 after purchasing an additional 7,760 shares during the period. Finally, Creative Planning increased its stake in shares of BioMarin Pharmaceutical by 20.9% during the third quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock worth $1,005,000 after purchasing an additional 2,475 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BMRN has been the subject of several recent research reports. Citigroup reduced their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. UBS Group upped their price target on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Robert W. Baird dropped their price objective on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. JPMorgan Chase & Co. decreased their target price on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $63.50 on Tuesday. The stock has a market cap of $12.10 billion, a price-to-earnings ratio of 38.02, a P/E/G ratio of 0.57 and a beta of 0.28. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The company has a 50 day simple moving average of $64.97 and a 200 day simple moving average of $72.08. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.